Floatz logo

Irinotecan

Pulmonary Sarcomatoid Carcinoma

Sichuan Cancer Hospital and Research InstituteSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Pulmonary Sarcomatoid Carcinoma cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Sichuan Cancer Hospital and Research Institute
Phase 2CCC
Carboplatin
Sichuan Cancer Hospital and Research Institute
Phase 2CCC
Toripalimab
Sichuan Cancer Hospital and Research Institute
Phase 2CCC

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →